Argenx Se (ARGX) Current Leases (2019 - 2026)
Argenx Se's (ARGX) quarterly Current Leases came in at $11.0 million in Q2 2026, up 45.04% YoY from $7.6 million in Q2 2025, and little changed on a QoQ basis from $11.0 million in Q4 2025.
Argenx Se (ARGX) Current Leases (2019 - 2026) Analysis & Trends
Argenx Se (ARGX) has 8 years of Current Leases data on file, last reported at $11.0 million in Q2 2026.
- Quarterly Current Leases rose 45.04% year-over-year to $11.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $11.0 million (up 45.04% YoY) and the FY2025 annual result came in at $11.0 million, up 68.38% from the prior year.
- Current Leases held at $11.0 million in Q2 2026, from $11.0 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $11.0 million in Q4 2025 to a low of $3.2 million in Q2 2023.
- A 5-year average of $6.3 million and a median of $5.9 million in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2023 — Current Leases dropped 8.42% — and 2024, when it surged 83.02%.
- Tracing ARGX's Current Leases over 5 years: stood at $3.4 million in 2022, then surged by 35.97% to $4.6 million in 2023, then soared by 40.62% to $6.5 million in 2024, then soared by 68.38% to $11.0 million in 2025, then changed by 0.0% to $11.0 million in 2026.
- The last three Current Leases figures came in at $11.0 million (Q2 2026), $11.0 million (Q4 2025), and $7.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.00 Mn |
| Dec 31, 2025 | 11.00 Mn |
| Jun 30, 2025 | 7.58 Mn |
| Dec 31, 2024 | 6.53 Mn |
| Jun 30, 2024 | 5.85 Mn |
| Dec 31, 2023 | 4.65 Mn |
| Jun 30, 2023 | 3.20 Mn |
| Dec 31, 2022 | 3.42 Mn |
| Jun 30, 2022 | 3.49 Mn |
| Dec 31, 2021 | 3.51 Mn |
| Jun 30, 2021 | 3.45 Mn |
| Dec 31, 2020 | 3.38 Mn |
| Jun 30, 2020 | 2.48 Mn |
| Dec 31, 2019 | 2.18 Mn |
| Jun 30, 2019 | 1.21 Mn |